| (19) |
 |
|
(11) |
EP 3 232 199 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A2) |
| (48) |
Corrigendum issued on: |
|
13.12.2017 Bulletin 2017/50 |
| (43) |
Date of publication: |
|
18.10.2017 Bulletin 2017/42 |
| (22) |
Date of filing: 17.08.2015 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Validation States: |
|
MA |
| (30) |
Priority: |
19.08.2014 JP 2014166593
20.04.2015 JP 2015085556
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
15833898.8 / 3192517 |
| (71) |
Applicants: |
|
- National University Corporation Okayama University
Kita-ku
Okayama-shi
Okayama 700-8530 (JP)
- ONO PHARMACEUTICAL CO., LTD.
Osaka-shi, Osaka 541-8526 (JP)
|
|
| (72) |
Inventors: |
|
- UDONO, Heiichiro
Okayama 700-8530 (JP)
- EIKAWA, Shingo
Okayama 700-8530 (JP)
- TOYOOKA, Shin-ichi
Okayama 700-8530 (JP)
|
| (74) |
Representative: Hoffmann Eitle |
|
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München
81925 München (DE) |
|
| |
|
|
|
Remarks: |
|
THIS APPLICATION WAS FILED ON 02-06-2017 AS A DIVISIONAL APPLICATION TO THE APPLICATION
MENTIONED UNDER INID CODE 62. |
|
| (54) |
METHOD FOR ENHANCING IMMUNE CELL FUNCTION AND METHOD FOR ASSESSING IMMUNE CELL MULTIFUNCTIONALITY |
(57) The present invention provides a method for enhancing immune cell function by activating
various immune cells ex vivo and provides immune cells with enhanced function. The
invention further provides an immune-related cell multifunctionality evaluation method.
A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is
capable of enhancing immune cell multifunctionality by increasing CD8+T cells having
a high ability to produce IL-2, TNFα, and IFNγ. The immune-related cell multifunctionality
may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug
selected from metformin, phenformin, and buformin, with control immune cells untreated
with the biguanide antidiabetic drug. When the multifunctionality of immune cells
treated with the biguanide antidiabetic drug selected from metformin, phenformin,
and buformin is determined to be significantly increased compared with the control,
it can be evaluated that the sensitivity of the immune cells to the therapeutic agent
is improved.